Physician profile
Sandhya Dhanjal
NPI 1093924417
$11,398.66
in general payments reported to CMS, 2019-2025
71 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,654 · 2020: $3,489 · 2021: $32.68 · 2022: $71.75 · 2023: $829 · 2024: $1,523 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108 · Education: $43.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.17 |
| Education | $43.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $821.89 | 2019-2024 | Opdivo, Opdualag |
| Genentech USA, INC. | $808.16 | 2019-2025 | Tecentriq, Alecensa, Venclexta |
| Novartis Pharmaceuticals Corporation | $803.14 | 2019-2025 | |
| Amgen INC. | $724.78 | 2019-2020 | |
| Janssen Biotech, INC. | $641.22 | 2019-2025 | Rybrevant, Erleada |
| Pfizer INC. | $584.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $557.51 | 2019-2024 | Keytruda, Welireg |
| Celgene Corporation | $491.71 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $464.73 | 2019-2025 | Tagrisso, Enhertu |
| Jazz Pharmaceuticals INC. | $330.62 | 2019-2025 | |
| Abbvie INC. | $307.58 | 2019-2025 | |
| Genzyme Corporation | $280.99 | 2019-2020 | |
| Astellas Pharma US INC | $273.92 | 2019-2025 | Padcev, Xospata |
| Lilly USA, LLC | $273.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $273.01 | 2020-2025 | Jemperli, Ojjaara, Zejula |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Dhanjal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.